Evidence map›Paper›PMID 37173454›Full record

ReviewWorld journal of urology2023

Eliciting men's preferences for decision-making relative to treatments of localized prostate cancer with a good or moderate prognosis.

Catherine Lejeune, Abderrahmane Bourredjem, Christine Binquet, Olivier Cussenot, Guillaume Boudrant, Frédéric Papillon, Franck Bruyère, Olivier Haillot, Nicolas Koutlidis, Sébastien Bassard and 7 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Catherine LejeuneCHU Dijon Bourgogne, Inserm, Université de Bourgogne, CIC 1432, Module Épidémiologie Clinique, 7 bd Jeanne d'Arc, BP 87900, 21000, Dijon, France. catherine.lejeune@u-bourgogne.fr.ORCID http://orcid.org/0000-0001-7351-0798
Abderrahmane BourredjemCHU Dijon Bourgogne, Inserm, Université de Bourgogne, CIC 1432, Module Épidémiologie Clinique, 7 bd Jeanne d'Arc, BP 87900, 21000, Dijon, France.
Christine BinquetCHU Dijon Bourgogne, Inserm, Université de Bourgogne, CIC 1432, Module Épidémiologie Clinique, 7 bd Jeanne d'Arc, BP 87900, 21000, Dijon, France.
Olivier CussenotAcademic Department of Urology, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, UPMC Sorbonne Universités, Paris, France.
Guillaume BoudrantDepartment of Urology, Sainte Marie Clinic, Chalon-sur-Saône, France.
Frédéric PapillonDepartment of Urology, Hospices Civils de Beaune, Beaune, France.
Franck BruyèreDepartment of Urology, CHU-Tours University Hospital, Tours, France.
Olivier HaillotDepartment of Urology, CHU-Tours University Hospital, Tours, France.
Nicolas KoutlidisDepartment of Urology, William Morey Hospital, Chalon-sur-Saône, France.
Sébastien BassardDepartment of Urology, William Morey Hospital, Chalon-sur-Saône, France.
Georges FournierDepartment of Urology, CHU Brest University Hospital, Brest, France.
Antoine ValeriDepartment of Urology, CHU Brest University Hospital, Brest, France.
Jean-Luc MoreauUrology Center, Nancy, France.
Bruno PierfitteUrology Center, Nancy, France.
Morgan MoulinDepartment of Urology, CHU University Hospital François Mitterrand, Dijon, France.
Célia BerchiNormandie Univ, UniCaen, Inserm, Anticipe, 14000, Caen, France.
Luc CormierDepartment of Urology, CHU University Hospital François Mitterrand, Dijon, France.
Inserm · FRCentre Hospitalier Régional Universitaire de Brest · FRUniversité de Tours · FRCentre Hospitalier de Beauvais · FRHôpital Sainte-Périne · FRSorbonne Université · FR

Funding

NCI NIH HHS [2012-09/293/AB-SD]
6 · The paper itself

Abstract

purposeIn diseases where there is no real consensus regarding treatment modalities, promoting shared decision-making can contribute to improving safety and quality of care. This is the case in low- or intermediate-risk localized prostate cancer (PC) treatment. The aim of this study was to investigate the preferences guiding men's decisions regarding the characteristics of the treatment strategies for PC to help physicians adopt a more patient-centered approach.

methodsThis prospective multicenter study used a discrete choice experiment (DCE). The attributes and the modalities were identified from a qualitative study and a literature review. Relative preferences were estimated using a logistic regression model. Interaction terms (demographic, clinical and socio-economic characteristics) were added to the model to assess heterogeneity in preferences.

results652 men were enrolled in the study and completed a questionnaire with 12 pairs of hypothetical therapeutic alternatives between which they had to choose. Men's choices were significantly negatively influenced by the risk of impotence and urinary incontinence, death, and the length and frequency of care. They preferred treatments with a rescue possibility in case of deterioration or recurrence and the use of innovative technology. Surprisingly, the possibility of undergoing prostate ablation negatively influenced their choice. The results also highlighted differences in trade-offs according to socio-economic level.

conclusionThis study confirmed the importance of considering patients' preferences in the decision-making process. It appears essential to better understand these preferences to allow physicians to improve communication and promote case-by-case decision-making.

Indexed as

Erectile DysfunctionProstatic NeoplasmsUrinary IncontinenceHumansMaleMulticenter Studies as TopicPrognosisProspective StudiesDiscrete choice experimentPreferenceProstate cancerTreatment

Identifiers

PMID37173454
OpenAlexW4376256415

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.